Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity

被引:1
|
作者
Nicolas, Olivier [1 ]
Moliner, Patricia [1 ]
Soubayrol, Patrick [1 ]
Vitse, Olivier [1 ]
Roy, Sebastien [2 ]
Cabanis, Marie-Jose [1 ]
Turner, Tim [3 ]
Klieber, Sylvie [1 ]
Muccio, Stephane [1 ]
Arabeyre, Catherine [1 ]
Brun, Priscilla [1 ]
机构
[1] Sanofi, Dept Translat Med & Early Dev, 371 Rue Prof Blayac, F-34184 Montpellier, France
[2] Sanofi, Dept Integrated Drug Discovery Isotope Chem, Paris, France
[3] Sanofi, MS Neurol Dev, Cambridge, MA USA
关键词
D O I
10.1007/s40261-023-01296-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Tolebrutinib is a covalent inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers of inflammation in multiple sclerosis. This excretion balance and metabolism study evaluated the metabolite profile of tolebrutinib in healthy male volunteers. Methods Six healthy volunteers received a 60-mg oral dose of [C-14]-tolebrutinib, and metabolite profiling of C-14-labeled metabolites was performed using a combination of liquid chromatography, mass spectrometry, and radioactivity assay methods. Results Tolebrutinib was rapidly and completely absorbed from the gastrointestinal tract, followed by rapid and extensive metabolism. Excretion via feces was the major elimination pathway of the administered radioactivity (78%). Tolebrutinib was highly metabolized, with 19 metabolites identified in human plasma. Phase 1 biotransformations were primarily responsible for the circulating metabolites in plasma. Seven metabolites that achieved exposure in plasma similar to or higher than the parent compound were characterized biochemically for inhibition of Bruton's tyrosine kinase activity. Metabolite M8 exceeded the exposure threshold of 10% (18%) of the total radioactivity but had little if any pharmacological activity. Metabolite M2 (4% of circulating radioactivity) retained the ability to irreversibly and potently inhibit Bruton's tyrosine kinase in vitro, similar to the parent compound. Tolebrutinib and metabolite M2 had short (3.5-h) half-lives but durable pharmacodynamic effects as expected for an irreversible antagonist. Conclusions Tolebrutinib was extensively metabolized to multiple metabolites. The hydroxylated metabolite M2 demonstrated similar inhibitory potency toward Bruton's tyrosine kinase as the parent compound. Both tolebrutinib and metabolite M2 likely contributed to pharmacological activity in vivo.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 50 条
  • [21] Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
    Johnson, Theodore R.
    Goulet, Lance
    Smith, Evan B.
    Yamazaki, Shinji
    Walker, Gregory S.
    Tan, Weiwei
    Li, Chunze
    Ni, Yao
    Bedarida, Gabriella
    Brega, Nicoletta
    Dalvie, Deepak
    Smith, Bill J.
    DRUG METABOLISM REVIEWS, 2011, 43 : 77 - 77
  • [22] ABSORPTION, EXCRETION, AND METABOLISM OF HB419-14C AFTER INTRAVENOUS AND ORAL APPLICATION TO HUMANS
    RUPP, W
    CHRIST, O
    HEPTNER, W
    ARZNEIMITTEL-FORSCHUNG, 1969, 19 (8A): : 1428 - &
  • [23] ABSORPTION DISTRIBUTION METABOLISM AND EXCRETION OF ORAL [14C]-IBREXAFUNGERP IN HEALTHY MALE SUBJECTS
    Azie, N.
    Angulo, D.
    Evans, P.
    Murphy, G.
    Ghahramani, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S12 - S12
  • [24] THE MASS BALANCE RECOVERY, ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-ORVEPITANT IN HEALTHY MALE SUBJECTS AFTER ORAL DOSING: RADIOSYNTHESIS OF [14C]-ORVEPITANT
    Carver, David
    Craig, Jo
    Lawrence, Ron
    Pawsey, Steve
    Cousins, Peggy
    Martos, Jose
    Shaw, Iain
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [25] Absorption, metabolism, distribution, and excretion of fimasartan ([14C]BR-A-657) following oral or intravenous administration to rats
    Lee, Joo-Han
    Chi, Yong-Ha
    Yoo, Byoung-Wook
    Kim, Ji-Han
    Tan, Hyun-Kwang
    Kim, Sang-Lin
    Bashir, Mohammad
    DRUG METABOLISM REVIEWS, 2006, 38 : 154 - 155
  • [26] Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
    He, Handan
    Tran, Phi
    Yin, Hequn
    Smith, Harold
    Batard, Yannick
    Wang, Lai
    Einolf, Heidi
    Gu, Helen
    Mangold, James B.
    Fischer, Volker
    Howard, Dan
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (03) : 536 - 544
  • [27] ABSORPTION, METABOLISM AND EXCRETION OF [14C]-GEMIGLIPTIN, A NOVEL DIPEPTIDYL PEPTIDASE 4 INHIBITOR, IN HUMANS
    Lee, Sung-Hack
    Kim, Namtae
    Ford, Gill
    Wood, Stuart
    Mair, Stuart
    Walker, Helen
    Shaw, Iain
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S78 - S78
  • [28] Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
    Kim, Namtae
    Patrick, Lorna
    Mair, Stuart
    Stevens, Lloyd
    Ford, Gill
    Birks, Vicky
    Lee, Sung-Hack
    XENOBIOTICA, 2014, 44 (06) : 522 - 530
  • [29] A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans
    Schwab, Dietmar
    Portron, Agnes
    Backholer, Zoe
    Lausecker, Berthold
    Kawashima, Kosuke
    CLINICAL PHARMACOKINETICS, 2013, 52 (06) : 463 - 473
  • [30] A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans
    Dietmar Schwab
    Agnes Portron
    Zoe Backholer
    Berthold Lausecker
    Kosuke Kawashima
    Clinical Pharmacokinetics, 2013, 52 : 463 - 473